TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Crescita Therpeutc ( (TSE:CTX) ) just unveiled an update.
Crescita Therapeutics reported its financial results for Q4 and fiscal year 2024, highlighting a revenue increase but a net loss due to higher operating expenses. Despite financial challenges, the company made strategic moves such as acquiring Aquafolia, securing a U.S. distribution agreement for Pliaglis, and amending a supply agreement with a major client, which are expected to enhance future profitability and market presence.
More about Crescita Therpeutc
Crescita Therapeutics Inc. is a Canadian commercial dermatology company focused on growth and innovation. It operates in the dermatology industry, offering a range of dermatological products and services. The company is known for its strategic market focus, including the acquisition of Aquafolia and partnerships in manufacturing and medical aesthetics.
YTD Price Performance: -11.86%
Average Trading Volume: 16,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$10.48M
For detailed information about CTX stock, go to TipRanks’ Stock Analysis page.